- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
Research at a glance
Top areas of exploration
- Parkinson Disease , 42 publications
- Supranuclear Palsy, Progressive , 18 publications
- Multiple System Atrophy , 14 publications
- Parkinsonian Disorders , 12 publications
Research activity
Focus
Dr. McFarland is an active member of the Center for Translational Research in Neurodegenerative Disease (CTRND) which aims to bring the bench closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and in particular the role of alpha-synuclein in cell toxicity and neurodegeneration. His current studies utilize both cellular and preclinical models to study genes and molecules that may affect brain pathology. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.
Active clinical trials
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease…
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 30 Years - N/A
- Sexes
- All
My publications
Filter publications
86 publications
2022
Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
Movement disorders : official journal of the Movement Disorder Society
PubMed • Publisher's site2022
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
Movement disorders : official journal of the Movement Disorder Society
PubMed • Publisher's site2022
Recommendations for Virtual Administration of the PSP Rating Scale.
Movement disorders : official journal of the Movement Disorder Society
PubMed • Publisher's site2022
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.
Trials
PubMed • Publisher's site2022
WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes.
Frontiers in cellular neuroscience
PubMed • Publisher's site